MARKET WIREYahoo Finance • 5h ago
Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure NewsYahoo Finance report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
Why ABT Stock advanced +1.56% Today — RQD Quant Desk Flash
$106.20 +1.56% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $106.75
Abbott Laboratories (ABT) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (56% profit margin, 12% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $180.95B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ABT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $106.20 (+1.56% 1D, market cap $180.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ABT ranks #24 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ABT compare to NVO and PFE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $173.31B) and PFE (Pfizer Inc.) posts a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ABT?
▼
Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $106.75 (+0.52%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 16.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+8.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABT)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY ABT SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 16.7% FCF Margin ($7.39B FCF) & 56.4% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)
Altman Z-Score 4.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution14/20 pts (-6 pt drag)
Cannibal Buyback (-1.80% YoY Shares) & executive Form 4 sales trim 6 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$102.61-0.2% Next Q
69
Q2 (-2Q)Grade B$102.45+0.6% Next Q
72
Q3 (-1Q)Grade B+$103.10+3% Next Q
74
CurrentGrade B+$106.20+7.8% Hist 90D α
77
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ABT Bull Thesis Could Fail
Even with a 77/100 (B+) score, ABT faces multiple-compression risk if 27.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 53.9% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($103.86) or 200D SMA ($101.51) invalidates the momentum regime and cuts Target Base ($115.28) toward Bear Floor ($87.08).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABT Stock advanced +1.56% Today — RQD Quant Desk Flash
Abbott Laboratories (ABT) advanced +1.56% to $106.20, trading at 48% of its 52-week range ($81.97 – $132.03). High-quality cash engine (56% profit margin, 12% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 48% of its 52-week range ($81.97 – $132.03) with RSI-14 at 54.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.5% around $106.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 56.4% gross margin and $7.4B annual free cash flow.
Live ABT Headlines & Catalysts
MARKET WIREChartMill • 8h ago
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable FundamentalsChartMill report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETrefis • 11h ago
Abbott Laboratories Earnings Ahead: What Past Reactions Say About The StockTrefis report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 14h ago
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.The Motley Fool report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvestor's Business Daily • 17h ago
Abbott Yo-Yoes On 'Choppy' Third Quarter As A Key Spinoff LoomsInvestor's Business Daily report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 20h ago
Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the MovementTradingKey report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 23h ago
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?Yahoo Finance report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 1d ago
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 2h ago
Abbott Touts Favorable Outcomes In Cardiovascular Device TrialsAbbott Laboratories (NYSE:ABT) reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego, demonstrating high procedur
CATALYSTYahoo • 4h ago
Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansionAbbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (ABT Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.32%⚡ TESTING RESISTANCE
2026-11-02O $102.6H $106.2L $102.6C $106.2VOL 7.29M
RES: $106.8SUP: $97.94SMA50: $103.9SMA200: $101.5
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
21.2%/yr Implied 5Y Growth
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ABT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABT)
Health Care Rank #24 of 1016
⚔️ NVO vs ABT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABT vs. NVO, PFE, VRTX, BMY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Abbott Laboratories (ABT) ranks #24 by composite RQD confidence (77/100, grade B+) and #11 by equity capitalization ($180.95B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with ABT at 77/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABT
ACTIVE
Abbott Laboratories | B+ | 77/100 | 27.7x | 56.4% | 11.9% | +1.56% | $180.95B | Benchmark Subject |
| NVO Novo Nordisk A/S | D+ | 57/100 | 32.8x | — | 9.9% | +2.20% | $173.31B | /nvo-vs-abt → |
| PFE Pfizer Inc. | B | 73/100 | 22.0x | 74.3% | 5.1% | +1.90% | $170.71B | /pfe-vs-abt → |
| VRTX Vertex Pharmaceuticals Incorporated | B+ | 80/100 | 34.6x | 86.2% | 20.0% | +3.50% | $136.87B | /vrtx-vs-abt → |
| BMY Bristol-Myers Squibb Company | C | 63/100 | 17.8x | 71.1% | 13.3% | +1.78% | $125.40B | /bmy-vs-abt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000001800In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abbott Laboratories (ABT) reported GAAP revenue of $44.33B (+5.7% vs. FY2024 revenue of $41.95B , and +10.5% cumulative change since FY2023) , GAAP net income of $6.52B, operating cash flow of $9.57B, and free cash flow of $7.39B (+16.4% YoY). On the balance sheet, ABT closed FY2025 with $86.71B in total assets against $9.90B in total debt (Altman Z-Score: 4.36, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $44.33B | $6.52B | $9.57B | $7.39B | $86.71B | $9.90B |
| FY2024 (FY) | 2024-12-31 | $41.95B | $13.40B | $8.56B | $6.35B | $81.41B | $12.63B |
| FY2023 (FY) | 2023-12-31 | $40.11B | $5.72B | $7.26B | $5.46B | $99.52B | $23.29B |
3. ABT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $106.20 (+1.56% 1D, market cap $180.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ABT ranks #24 in composite RQD confidence.
How does ABT compare to NVO and PFE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $173.31B) and PFE (Pfizer Inc.) posts a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABT?
Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABT trading relative to its 50-day, 200-day, and 52-week technical levels?
ABT last traded at $106.20 (+1.56% on volume of 8,440,815 shares), positioning the stock +2.25% above its 50-day simple moving average ($103.86) and +4.62% above its 200-day simple moving average ($101.51). Across its 52-week range of $81.97 to $132.03, ABT sits at the 48.4% percentile with a 14-day RSI of 54.2 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($100.36 to $112.04).
ABT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ABT stock moving today?
Why ABT Stock advanced +1.56% Today — RQD Quant Desk Flash. High-quality cash engine (56% profit margin, 12% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 77/100 (B+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ABT — Abbott Laboratories: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:09:10Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ABT scores 77 out of 100 with a letter grade of B+, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are: Fundamental Cash Engine 16/20 (ROIC 11.9%; FCF yield 4.09%), Whale 13F Flow 15/20 (institutional accumulation and options positioning), Insider Conviction 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 16/20 (beta 0.99; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 4.36; Piotroski F 8/9; Debt/Equity 0.19).
For a prospective investor, the strongest support comes from the cash engine and balance sheet pillars, which both sit at 16/20, alongside a beta near 1.0 that indicates market-like volatility relative to the broader market. The weakest pillar is Insider Conviction at 14/20, meaning insider and congressional flow is supportive but less decisive than the operating and balance sheet evidence. Valuation is the principal tradeoff: the stock trades at a trailing P/E of 27.7 and EV/EBITDA of 18.4, so upside depends on sustaining earnings growth rather than on a low entry multiple. The rating is a quantitative summary of the provided data and is not a recommendation to act.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $44328.0M | $8053.0M | $6524.0M | N/A | $7395.0M | $8522.0M | $9896.0M |
| FY 2024 | $41950.0M | $6825.0M | $13402.0M | N/A | $6351.0M | $7616.0M | $12625.0M |
| FY 2023 | $40109.0M | $6478.0M | $5723.0M | N/A | $5456.1M | N/A | $23287.8M |
Per the market data, gross margin is 56.4%, operating margin 18.2%, and net margin 14.7%, with ROIC of 11.9% and FCF yield of 4.09%. Per the Roarable RQD rating, the Altman Z-Score is 4.36 and the Piotroski F-Score is 8/9, with Debt/Equity at 0.19. Reported debt declined from $23287.8M (FY 2023) to $9896.0M (FY 2025) while cash rose to $8522.0M, and FY 2024 net income ($13402.0M) exceeds its operating income ($6825.0M), a divergence the source data does not explain.
Open Questions
- What is the heart failure news referenced in the Yahoo Finance headline, and what valuation impact does the source attribute to it?
- What is the scope and timing of the spinoff referenced in the Investor's Business Daily coverage?
- What drove the divergence between FY 2024 net income ($13402.0M) and operating income ($6825.0M), and is it recurring?
- Why do EPS figures show N/A across all reported periods when trailing EPS is listed at 3.77?
- Which specific institutional, insider, and congressional transactions underpin the RQD pillar scores of 15/20 and 14/20?
ABT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Abbott Laboratories (ABT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 5h ago
Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News Yahoo Finance report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 8h ago
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals ChartMill report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 11h ago
Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock Trefis report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 14h ago
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. The Motley Fool report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investor's Business Daily • 17h ago
Abbott Yo-Yoes On 'Choppy' Third Quarter As A Key Spinoff Looms Investor's Business Daily report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 20h ago
Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement TradingKey report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 23h ago
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? Yahoo Finance report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ABT Bull vs. Bear Conversation Board — What's Your Call at $106.20?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABT 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $123.39 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ABT (B+ • RQD 77/100) a Buy at $104.57?
Welcome to the ABT (Abbott Laboratories) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $82.61 (-21.0%)
Spot @ $104.57 Pump the brakes on ABT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ABT, but look at what you are paying: 27.7x trailing P/E with 56.4% gross margins. Unless Abbott Laboratories expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $129.67 (+24.0%)
Spot @ $104.57 ABT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ABT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $104.57 (52-wk range $81.97 - $132.03), any beat on forward guidance forces shorts and underweight funds to chase.